Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 1.00 |
| ▸ | PIM1 | P11309 | 9/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 8/20 | 1.00 |
| ▸ | CDK2 | P24941 | 5/20 | 1.00 |
| ▸ | CDC7 | O00311 | 4/20 | 1.00 |
| ▸ | PRKACA | P17612 | 4/20 | 1.00 |
| ▸ | HIPK2 | Q9H2X6 | 4/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.68 |
| ▸ | CDK1 | P06493 | 4/20 | 0.68 |
| ▸ | GSK3A | P49840 | 4/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.68 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.68 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.68 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.68 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.68 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.68 |
| ▸ | CLK2 | P49760 | 3/20 | 0.68 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640320 | 0.84 | ROCK2 (0.71) | GSK3BPIM1ROCK2CDK2CDC7 | |
| SCHEMBL4297819 | 0.83 | ROCK2 (0.72) | GSK3BPIM1ROCK2CDK2CDC7 | |
| SCHEMBL3636482 | 0.83 | GSK3B (0.71) | GSK3BPIM1ROCK2CDK2CDC7 | |
| SCHEMBL3633638 | 0.81 | ROCK2 (1.00) | GSK3BPIM1ROCK2CDK2CDC7 | |
| SCHEMBL3634021 | 0.79 | ROCK2 (0.83) | GSK3BPIM1ROCK2CDK2CDC7 | |
| SCHEMBL3668378 | 0.77 | ROCK2 (1.00) | GSK3BPIM1ROCK2CDK2CDC7 | |
| SCHEMBL3635068 | 0.77 | ROCK2 (0.77) | GSK3BPIM1ROCK2CDK2CDC7 | |
| SCHEMBL16241021 | 0.77 | ROCK2 (0.72) | GSK3BPIM1ROCK2CDK2CDC7 | |
| SCHEMBL4288764 | 0.77 | ROCK2 (0.63) | GSK3BPIM1ROCK2CDK2CDC7 | |
| SCHEMBL3634019 | 0.76 | ROCK2 (1.00) | GSK3BPIM1ROCK2CDK2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | claimed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | claimed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | claimed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | GSK3B 1/4885PIM1 11/4885ROCK2 48/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | GSK3B 1/4885PIM1 11/4885ROCK2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.